0001079973-16-001279.txt : 20161114 0001079973-16-001279.hdr.sgml : 20161111 20161114142220 ACCESSION NUMBER: 0001079973-16-001279 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161114 DATE AS OF CHANGE: 20161114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProtoKinetix, Inc. CENTRAL INDEX KEY: 0001128189 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943355026 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32917 FILM NUMBER: 161993655 BUSINESS ADDRESS: STREET 1: 9176 SOUTH PLEASANTS HIGHWAY CITY: ST. MARYS STATE: WV ZIP: 26170 BUSINESS PHONE: 604-926-6627 MAIL ADDRESS: STREET 1: 9176 SOUTH PLEASANTS HIGHWAY CITY: ST. MARYS STATE: WV ZIP: 26170 FORMER COMPANY: FORMER CONFORMED NAME: RJV NETWORK INC DATE OF NAME CHANGE: 20010130 10-Q 1 pktx_10q-093016.htm FORM 10-Q FOR THE PERIOD ENDED 9/30/2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2016

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ___________________.

Commission file number:

PROTOKINETIX, INCORPORATED

(Exact name of registrant as specified in its charter)

Nevada		94-3355026
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

9176 South Pleasants Highway

St. Marys, West Virginia 26170

(Address of principal executive offices)

304-299-5070

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☐	(Do not check if a smaller reporting company)	Smaller reporting company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 14, 2016, there were 227,452,433 shares of ProtoKinetix, Incorporated that were issued and outstanding.

PROTOKINETIX, INCORPORATED

TABLE OF CONTENTS

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Unaudited Condensed Balance Sheets	3

Unaudited Condensed Statements of Operations	4

Unaudited Condensed Statement of Stockholders' Equity	5

Unaudited Condensed Statements of Cash Flows	6

Notes to Unaudited Condensed Financial Statements	7

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3. Quantitative and Qualitative Disclosures About Market Risk	25

Item 4. Controls and Procedures	25

PART II

OTHER INFORMATION

Item 1. Legal Proceedings	26

Item 1A. Risk Factors	26

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3. Defaults Upon Senior Securities	26

Item 4. Mine Safety Disclosure	26

Item 5. Other Information	26

Item 6. Exhibits	27

Signatures	28

PROTOKINETIX, INC.

(A Development Stage Company)

BALANCE SHEETS

(Unaudited)


	September 30, 2016			December 31, 2015
ASSETS
Current Assets
Cash	$	88,965		$	371,072
Accounts receivable (Note 3)		-			8,023
Prepaid expenses and deposits (Note 11)		91,429			397
Total current assets		180,394			379,492

Intangible assets (Note 4)		75,599			70,260

Total assets	$	255,993		$	449,752
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities (Note 10)	$	40,386		$	45,388
Total current liabilities		40,386			45,388
Stockholders' Equity
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 226,202,433 and 216,602,433 shares issued and outstanding as at September 30, 2016 and December 31, 2015 respectively (Note 9)		1,210			1,159
Additional paid-in capital		28,459,913			27,498,836
Accumulated deficit		(28,245,516	)		(27,095,631	)
Total stockholders' equity		215,607			404,364
Total liabilities and stockholders' equity	$	255,993		$	449,752

Basis of Presentation – Going Concern Uncertainties (Note 1)

Commitments and Contingency (Note 11)

Subsequent Event (Note 12)

See Notes to Financial Statements

PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

For the Three and Nine Months Ended September 30, 2016 and 2015

	Three months ended September 30, 2016			Three months ended September 30, 2015			Nine months ended September 30, 2016			Nine months ended September 30, 2015



EXPENSES
Amortization – intangible assets (Note 4)	$	750		$	-		$	2,250		$	-
Consulting fees (Note 10)		-			15,000			-			65,000
General and administrative		17,341			23,119			70,441			105,468
Interest		-			-			-			3,969
Professional fees (Note 10)		39,664			49,325			147,977			219,848
Research and development		174,957			29,850			355,089			101,970
Share-based compensation (Note 10)		199,365			117,485			574,128			290,728

		(432,077	)		(234,779	)		(1,149,885	)		(786,983	)


OTHER ITEMS
Gain on settlement of short-term loan (Note 5)		-			7,272			-			7,272
Net loss for the period	$	(432,077	)	$	(227,507	)	$	(1,149,885	)	$	(779,711	)

Net loss per common share (basic and diluted)	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.00	)

Weighted average number of common shares outstanding (basic and diluted)		222,088,754			202,076,618			219,242,214			194,626,737

See Notes to Financial Statements

PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENT OF STOCKHOLDERS' EQUITY

(Unaudited)

For the Period from December 31, 2015 to September 30, 2016

	Common Stock
	Shares		Amount		Issuable shares		Amount		Additional paid-in capital		Accumulated deficit			Total
Balance, December 31, 2015		216,602,433	$	1,159		-	$	-	$	27,498,836	$	(27,095,631	)	$	404,364

Issuance of common stock for services		100,000		1		-		-		6,999		-			7,000

Fair value of compensatory options issued		-		-		-		-		574,128		-			574,128

Issuance of common stock pursuant to private placement offering		9,500,000		50		-		-		379,950		-			380,000

Net loss for the period		-		-		-		-		-		(1,149,885	)		(1,149,885	)

Balance, September 30, 2016		226,202,433	$	1,210		-	$	-	$	28,459,913	$	(28,245,516	)	$	215,607

See Notes to Financial Statements

PROTOKINETIX, INC.

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

For the Nine Months Ended September 30, 2016 and 2015

	Nine Months ended September 30, 2016			Nine Months ended September 30, 2015

CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$	(1,149,885	)	$	(779,711	)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization – intangible assets		2,250			-
Issuance and amortization of common stock for services		7,000			69,000
Fair value of compensatory options granted		574,128			290,728
Contribution of services		-			8,780
Gain on settlement of short term loans		-			(7,272	)

Changes in operating assets and liabilities:
Accounts receivable		8,023			(2,486	)
Prepaid expenses and deposits		(91,032	)		(637	)
Accounts payable and accrued liabilities		(5,002	)		35,557

Net cash used in operating activities		(654,518	)		(386,041	)

CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of intangible assets		(7,589	)		(40,000	)

Net cash used in investing activities		(7,589	)		(40,000	)


CASH FLOWS FROM FINANCING ACTIVITIES
Short-term loan repayments		-			(63,250	)
Issuance of common stock for cash		380,000			652,500

Net cash from financing activities		380,000			589,250

Net change in cash		(282,107	)		163,209

Cash, beginning of period		371,072			317

Cash, end of period	$	88,965		$	163,526

Cash paid for interest	$	-		$	-

Cash paid for income taxes	$	-		$	-
Supplementary information – non-cash transactions:
Common stock issued for consulting services	$	7,000		$	69,000
Common stock returned to treasury		-			25,000
Common stock issued for past subscriptions		-			25,000
Common stock issued to settle promissory note		-			100,000
Fair value of warrants issued for intangible asset		-			25,000

See Notes to Financial Statements

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 1. Basis of Presentation – Going Concern Uncertainties

ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

A Cease Trade Order ("CTO") was issued in respect of the Company's securities by the British Columbia Securities Commission ("BCSC") on May 9, 2013 based on the Company's failure to file annual financial statements for the year ended December 31, 2012 by the deadline of April 1, 2013. The Company has since completed all of the required filings for annual and interim periods and received a full Revocation Order from the BCSC during the year ended December 31, 2015.

During the nine month period ended September 30, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the BCSC.

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2016. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans.

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K, filed March 30, 2016, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 2. Summary of Significant Accounting Policies (cont'd)

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At September 30, 2016 there were no other assets or liabilities subject to additional disclosure.

Income Taxes

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 "Income Taxes." Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 2. Summary of Significant Accounting Policies (cont'd)

Intangible assets – patent and patent application costs

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

As at September 30, 2016, the Company does not hold any intangible assets with indefinite lives.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2016.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 28,600,000 stock options (September 30, 2015 – 14,600,000) and 6,500,000 warrants (September 30, 2015 – 12,262,500) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

Share-Based Compensation

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 2. Summary of Significant Accounting Policies (cont'd)

Share-Based Compensation (cont'd)

The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 "Stock-Based Transactions with Nonemployees", which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common stock

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete.

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Recent Accounting Pronouncements

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity's ability to continue as a going concern within one year of the date of issuance of the entity's financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity's ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company's financial statements.

Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company is reviewing this update to determine the impact it will have on its financial statements.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 2. Summary of Significant Accounting Policies (cont'd)

Recent Accounting Pronouncements (cont'd)

Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.

Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy is effective December 16, 2016. The Company is evaluating this guidance and believes it will have little impact on the presentation of its financial statements.

Accounting Standards Update 2015-02 - Consolidation (Topic 810) - Amendments to the Consolidation Analysis. This update provides guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard which has little impact on the presentation of its financial statements.

Accounting Standards Update 2015-01 - Income Statement—Extraordinary and Unusual Items (Subtopic 225-20). This Update is part of an initiative to reduce complexity in accounting standards (the Simplification Initiative). This Update eliminates from GAAP the concept of extraordinary items. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard.

Note 3. Accounts Receivable

Accounts receivable consists of refundable sales tax paid on purchases made in Canada.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 4. Intangible Assets

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period ended September 30, 2016, the Company recorded $2,250 (September 30, 2015 - $nil) in amortization expense associated with the Patents.

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights"). In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $11,933 in direct costs relating to the Patent Application Rights, $5,173 of which were incurred during the nine month period ended September 30, 2016.

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.

During the nine month period ended September 30, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells" (the "New Patent Application Rights"). In exchange for the New Patent Application Rights, the Company agreed to pay $1.00 (paid). The Company incurred $2,416 in direct costs relating to the New Patent Application Rights.

No amortization was recorded on the Patent Application Rights or the New Patent Application Rights to September 30, 2016.

Note 5. Convertible Note Payable and Credit Facility

Convertible Note Payable

On July 1, 2011, the Company executed a loan agreement under which the Company issued to a corporation an 8% convertible promissory note in exchange for $300,000. The note holder had the right to demand payment of outstanding principal and interest at any time with a 30-day grace period. The note was due and payable no later than June 30, 2016, and was convertible into shares of the Company's common stock at $0.025 per share. No beneficial conversion feature was applicable to this convertible note.

During the year ended December 31, 2014, the Company and the corporation commenced discussions in regards to the settlement of the convertible note through extinguishment. A settlement agreement was finalized during the year ended December 31, 2015, but the Company has accounted for the transaction as at December 31, 2014. The settlement agreement stipulated that the convertible note plus accrued interest of $84,000 (included in accounts payable and accrued liabilities as at December 31, 2014) was to be settled through the issuance of 3,840,000 shares of the Company's common stock. The fair value of the shares was determined to be $192,000 ($0.05 per share) and the Company recognized a gain on settlement in the amount of $192,000 as at December 31, 2014.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 5. Convertible Note Payable and Credit Facility (cont'd)

The settlement agreement also stipulated the payment of $161,750 to the corporation to settle other amounts included in accounts payable and accrued liabilities and short-term loans, all of which had been paid as at December 31, 2015.

On June 17, 2014, the Company executed a loan agreement under which the Company issued an 8% convertible promissory note in exchange for an initial amount of $10,000, with the ability to be increased to $100,000, to the Company`s President and CEO. During the year ended December 31, 2014, additional amounts totaling $90,000 were advanced, $23,500 of which was paid directly to settle certain short-term loans outstanding. The note holder had the right to demand payment of outstanding principal and interest at any time with a 30-day grace period. The note was due and payable no later than December 31, 2015, and was convertible into shares of the Company's common stock at $0.25 per share. No beneficial conversion feature was applicable to this convertible note. On July 1, 2015, the Company`s board of directors approved an adjustment to the conversion price from $0.25 to $0.08. During the year ended December 31, 2015, the Company issued 1,250,000 shares of the Company's common stock at the adjusted conversion price of $0.08 per share to settle the promissory note. A gain of $7,272 was recognized associated with interest forgiven on the note.

Credit Facility

On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia. Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly. The Company's President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells". As at September 30, 2016, the balance outstanding was $nil.

Note 6. Common Shares Issued for Services

During the nine month periods ended September 30, 2016 and 2015, the Company issued shares of common stock for services and other value rendered as follows:

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

2015	Number of Shares		Value per Share		Total

February 2015		1,000,000	$	0.04	$	40,000
June 2015		100,000	$	0.07	$	7,000
		1,100,000			$	47,000

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 7. Stock Options

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the "Plan"). The Board of Directors adopted this plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.

Under the Plan, the lesser of: (i) 20,000,000 shares; or (ii) 10% of the total number of the Company's common shares outstanding are reserved to be issued upon the exercise of options or the grant of stock bonuses. As such, the Plan is subject to an absolute cap of 20,000,000 shares. The Plan includes two types of options; options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options, and options which are not intended to qualify as incentive options are referred to as non-qualified options.

As of September 30, 2016, 16,600,000 options and 2,000,000 shares of common stock have been granted under the Plan.

The Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors. In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted. The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the Plan. The committee may determine the purchase price of the shares of common stock covered by each option and determine the fair market value per share. The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the Plan. The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the Plan.

In the event that a change, such as a stock split, is made in the Company's capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option. The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock. Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the Plan shall terminate as of a date fixed by the committee.

The exercise price of any option granted under the Plan must be no less than 100% of the "fair market value" of the Company's common stock on the date of grant. Any incentive stock option granted under the Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant.

The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property. The committee determines whether or not property other than cash or common stock may be used to purchase the shares underlying an option and shall determine the value of the property received.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 7. Stock Options (cont'd)

Stock option transactions are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2015		14,600,000			0.05		0.03
Options granted		15,000,000			0.08		0.05
Options expired		(1,000,000	)		0.10		0.03
Outstanding, September 30, 2016		28,600,000			0.06		0.04	2.92

The fair values of the stock options granted during the nine month periods ended September 30, 2016 and 2015 were estimated using the Black-Scholes Option Pricing Model. The weighted average assumptions used in the pricing model for these options are as follows:

	September 30, 2015			September 30, 2016
Risk-free interest rate		0.81	%		0.56	%
Dividend yield		0.00	%		0.00	%
Expected stock price volatility		125.00	%		125.00	%
Expected forfeiture rate		0.00	%		0.00	%
Expected life	4.81 years			3.94 years

The following non-qualified stock options were outstanding and exercisable at September 30, 2016:

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
	$
February 25, 2017		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2017		0.10		1,000,000		1,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		11,250,000
				28,600,000		22,850,000

As at September 30, 2016, the aggregate intrinsic value of the Company's stock options is $398,000 (December 31, 2015 – $350,000). The weighted average fair value of stock options granted during the nine month period ended September 30, 2016 is $0.05 (2015 - $0.03).

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 8. Warrants

Warrant transactions for the nine month period ended September 30, 2016 are summarized as follows:

	Number of Warrants			Weighted Average Exercise Price
Balance, December 31, 2015		8,700,000		$	0.11
Expired		(2,200,000	)		0.10
Balance, September 30, 2016		6,500,000		$	0.11

The following warrants were outstanding and exercisable as at September 30, 2016:

Number of Warrants	Exercise Price ($)	Expiry Date
500,000	0.25	November 8, 2018
6,000,000	0.10	April 22, 2020
6,500,000

Note 9. Stockholders' Equity

The Company is authorized to issue 400,000,000 (December 31, 2015 – 400,000,000) shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2016 (December 31, 2015 - $nil).

During the nine month period ended September 30, 2016, the Company:

a)	Issued 100,000 shares of common stock with a fair value of $7,000 ($0.07 per share) pursuant to a consulting agreement entered into on March 1, 2015 (Note 11(b)).

b)	Issued 4,150,000 shares of common stock to investors (one of which was the President and CEO of the Company) at $0.04 per share for gross proceeds of $166,000.

c)	Issued 5,350,000 shares of common stock to investors (one of which was the President and CEO of the Company) at $0.04 per share for gross proceeds of $214,000.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 10. Related Party Transactions and Balances

During the nine month period ended September 30, 2015, the Company:

Entered into a directorship agreement effective February 25, 2015 with a newly appointed director of the Company. Pursuant to the agreement, the director was issued 1,000,000 shares of common stock as an engagement fee and was entitled to a compensatory service fee. The director was also entitled to 1,000,000 stock options on signing exercisable into common shares of the Company for a period of 3 years at a price of $0.05 per share.

During the nine month period ended September 30, 2015, the director provided $8,780 in contributed services, which were recorded as professional fees against additional paid-in capital.

Entered into a consulting agreement dated March 30, 2015 (effective January 1, 2015) with the Company's President and CEO whereby he was compensated at a nominal amount of $1 for services through to December 31, 2015. The agreement also stipulates a termination fee that would pay the Company's President and CEO $100,000 if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 plus 2.5% of the aggregate transaction value of the change of control.

Entered into a consulting agreement dated March 30, 2015 (effective January 1, 2015) with the Company's CFO whereby she was compensated at a monthly fee of $4,000 for services through to December 31, 2018 ($4,000 per month for fiscal 2015, then increased by not less than 5% each year thereafter). A total of $36,000 was paid or accrued to the Company's CFO during the nine month period ended September 30, 2015. She was also entitled (as of February 26, 2015) to 4,000,000 stock options exercisable into common shares of the Company for a period of 5 years at a price of $0.04 per share. The options vested monthly in tranches of 400,000 over 10 months.

She was also entitled to an additional 2,000,000 stock options exercisable for a period of 2 years at a price of $0.04 per share that will vest only upon a change in control. If terminated without cause, the agreement also stipulates a termination fee that would pay the Company's CFO three times her monthly consulting fee in effect as of the date of termination or if terminated without cause after January 1, 2016, six times her monthly consulting fee in effect as of the date of termination. In the case of termination upon a change of control event, the termination fee would be equal to two times the amount that she would receive as if terminated without cause.

Entered into a directorship agreement effective July 1, 2015 with a newly appointed director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options on signing exercisable into common shares of the Company for a period of 2 years at a price of $0.10 per share. The options vested in monthly installments of 166,666 options beginning July 31, 2015 with the final 166,670 options vesting on December 31, 2015.

e)	Recognized $137,810 in share-based compensation associated with stock options granted to key management personnel.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 10. Related Party Transactions and Balances (cont'd)

During the nine month period ended September 30, 2016, the Company:

Entered into a consulting agreement with an effective date of January 1, 2016 with the Company's President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company's President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2016.

Entered into a consulting agreement with an effective date of January 1, 2016 with the Company's CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company's CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2016. A total of $54,000 was paid or accrued to the Company's CFO during the nine month period ended September 30, 2016 and is included in professional fees.

Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2016.

d)	Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.

As at September 30, 2016 and December 31, 2015, the following amounts are due to related parties:

			September 30, 2016				December 31, 2015
Clarence Smith (CEO)	Accounts payable and accrued liabilities		$	1,359			$	327

Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 11. Commitments and Contingency

As at September 30, 2016, the Company has the following commitments:

Entered into a consulting agreement with an effective date of January 1, 2016 whereby the Company would pay the consultant $7,000 per month for providing research and development services. Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options vest in equal instalments on a quarterly basis beginning March 31, 2016.

Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year for providing public relations services. The consultant was also entitled to 400,000 shares of common stock, which were issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (100,000 shares issued during the nine month period ended September 30, 2016 (Note 9)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10 for a period of 5 years. The stock options vested at the rate of 25% every 3 months over the term of the agreement.

Entered into a royalty agreement with the Governors of the University of Alberta (the "University") whereby the University had developed certain intellectual property (the "Additional Patent Rights") in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the "Royalty") derived from products arising from the Patent Rights. The Company will have the right and option for two years from the earlier of September 1, 2015 or the first date that the University publishes its research related to the Additional Patent Rights to buy out all of the University's Royalty for consideration of the aggregate sum of CDN $5,000,000.

Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year for providing research and development services.

Entered into a Collaborative Research Agreement (the "CREA") effective May 31, 2016 with The University of British Columbia ("UBC") for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and will be required to pay an additional CAD $201,500 within 12 months from the effective date of the CREA in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days' written notice. As at September 30, 2016, a total of $87,132 is included in prepaid expenses and deposits.

Entered into a series of Study Contracts (the "Contracts") with ITR Laboratories Canada ("ITR") effective April 19, 2016 whereby ITR will provide research services to the Company. Pursuant to the terms of the Contracts, 50% of the total cost of the Contracts was payable on authorization. The total fees associated with the Contracts is CAD $60,600 and as at September 30, 2016, the Company owed CAD $18,000 ($12,310).

The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities. The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements. No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

PROTOKINETIX, INC.

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2016

Note 12. Subsequent Event

Subsequent to the nine month period ended September 30, 2016, the Company:

Entered into a consulting agreement for business development services effective October 1, 2016. The consultant was granted 300,000 stock options exercisable into common shares of the Company at a price of $0.08 per share for a period of two years. The options will vest in monthly installments of 100,000 options beginning October 31, 2016 with the final 100,000 options vesting on December 31, 2016.

Issued 1,250,000 shares of common stock to the President and CEO of the Company at $0.04 per share for gross proceeds of $50,000.00.

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context requires otherwise, references in this document to "ProtoKinetix", "we", "our", "us" or the "Company" are to ProtoKinetix, Incorporated.

The following discussion provides information regarding the results of operations for the nine month periods ended September 30, 2016 and 2015, and our financial condition, liquidity and capital resources as of September 30, 2016, and December 31, 2015. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Quarterly Report on Form 10-Q include "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"). All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as "may," "expect," "estimate," "project," "plan," "believe," "intend," "achievable," "anticipate," "will," "continue," "potential," "should," "could," and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward looking statements as a result of certain factors, including, among others:

•

Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

•

Our plans to develop and commercialize products from the AAGP™ molecule;

•

Ongoing testing of the AAGP™ molecule;

•

Our intellectual property position;

•

Our commercialization, marketing and manufacturing capabilities and strategy;

•

Our ability to retain key members of our senior management and key scientific consultants;

•

The effects of competition;

•

Our potential tax liabilities resulting from conducting business in the United States and Canada;

•

The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and

•

Our common stock's limited trading history.

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Business Overview

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs™. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs™ in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP™ to market.

Results of Operations

The following table shows selected financial data and operating results for the periods noted. Following the table, please see management's discussion of significant changes.

	For the Nine Months Ended
	September 30,
	2016			2015
Revenues	$	-		$	-
Cost of sales		-			-
Gross (loss) profit		-			-
Operating Expenses
Amortization	$	2,250		$	-
Consulting Fees		-			65,000
General and Administrative		70,441			105,468
Interest Expense		-			3,969
Professional Fees		147,977			219,848
Research and Development		355,089			101,970
Share-Based Compensation		574,128			290,728
Total operating expenses		1,149,885			(786,983	)
Loss from Operations		(1,149,885	)		(786,983	)

Other Expense
Foreign Exchange Loss		-			-
Total other expenses		-			-

Other Income
Gain on Settlement of Short-Term Loan		-			7,272
Total other income		-			-
Net Loss	$	(1,149,885	)		(779,711	)

Revenues

We had no revenues for the nine month periods ended September 30, 2016 and 2015.

Gross Profit and Expenses

The Company's net loss was $1,149,885 for the nine month period ended September 30, 2016 compared to $779,711 for the nine month period ended September 30, 2015. These expenses were primarily incurred for professional fees, share-based compensation recognized on stock options granted, research and development and other general and administrative expenses. Significant changes from the prior nine month period ended September 30, 2015 include:

Consulting fees decreased by $65,000 from $65,000 to $nil primarily as a result of a change in terms of consulting contracts entered into for the current year.

General and administrative expenses decreased by $35,027 from $105,468 to $70,441 primarily as a result of a decrease in travel expenses associated with the office relocation, the lifting of the Cease Trade Order in British Columbia (the "CTO") and the changing of the management of the Company.

Interest expense decreased by $3,969 from $3,969 to $nil as a result of a decrease in short-term loans and notes payable.

Professional fees decreased by $71,871 from $219,848 to $147,977 primarily as a result of a decrease in legal fees associated with the CTO and company operations.

Research and development increased by $253,119 from $101,970 to $355,089 primarily as a result of management's intention to move the Company forward in the development of the AAGP™ molecule.

Share-based compensation increased by $283,400 from $290,728 to $574,128 primarily as a result of stock options granted pursuant to consulting contracts being entered into for the current year.

Liquidity and Capital Resources

The following summarizes our liquidity at September 30, 2016 and December 31, 2015:

	September 30, 2016		December 31, 2015

Cash	$	88,965	$	371,072

Working Capital	$	140,008	$	334,104

At September 30, 2016, we had $88,965 in cash and $180,394 in total current assets. As of September 30, 2016 we had a working capital position of $140,008. Based upon our working capital equity as of September 30, 2016, we require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives. There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business.

The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

Sources and Uses of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities increased by $268,477 from $386,041 to $654,518 for the nine months ended September 30, 2015 and 2016, respectively. This increase was predominantly due to an increase in cash-based expenditures relating to the Company's current research contract with the University of British Columbia and study contracts with ITR Laboratories Canada as well as the Company's efforts to reduce historical accounts payable and accrued liabilities concurrent with the change in management completed in 2015.

Net Cash Used in Investing Activities

Net cash used in investing activities was $7,589 for the nine month period ended September 30, 2016 while the Company had net cash used in investing activities of $40,000 for the comparative period. The difference is attributable to a decrease in the purchase of intangible assets.

Net Cash Provided by Financing Activities

Net cash provided by financing activities decreased by $209,250 from $589,250 to $380,000 for the nine months ended September 30, 2015 and 2016, respectively due to a decrease in private placements and short-term loan repayments.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States ("U.S. GAAP"), which contemplate continuation of the Company as a going concern. The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock. However the Company's common stock is at a low price and is not actively traded.

Off-Balance Sheet Arrangements

None.

Contractual Obligations

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

While all of the significant accounting policies are important to the Company's financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

Share-Based Compensation

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the "Plan"). The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services outside of the Plan, and beginning July 1, 2015 pursuant to the Plan. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

Sales and Marketing

The Company is currently not selling or marketing any products.

Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine months ended September 30, 2016.

Contractual Obligations

As a smaller reporting company as defined by Item 10 of Regulation S-K, we are not required to provide the information requested by paragraph (a)(5) of this Item.

Item 3. Quantitative and Qualitative Disclosure about Market Risk

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

Item 4. Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (the "1934 Act") is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of September 30, 2016 (the end of the period covered by this report). Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC's rules and forms.

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated by the SEC under the 1934 Act) during the nine months ended September 30, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Other than reported in the Company's Quarterly Report on Form 10-Q for the nine month period ended September 30, 2016, the Company and its management are not aware of any regulatory or legal proceedings or investigations pending involving the Company, any of its subsidiaries or affiliates, or any of their respective officers, directors or employees.

Item 1A. Risk Factors

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. However, our current risk factors are set forth in our Annual Report on Form 10-K for the year ended December 31, 2015 as filed with the SEC on March 30, 2016, and such risk factors are incorporated herein by this reference.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Between September 2, 2016 and November 4, 2016, the Company issued 4,750,000 shares of its common stock at a price of $0.04 per share to accredited investors in a private placement transaction for gross proceeds of $190,000, of which, Clarence E. Smith, the Company's President and Chief Executive Officer, personally participated in the offering for the purchase of 4,250,000 shares. The Company relied on the exemptions under Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder for the issuance of common stock. There was no general solicitation in connection with this offer and sale and no commission or other remuneration was paid on the issuance of the common stock. A Form D was filed on September 16, 2016.

On October 6, 2016, the Company issued options to purchase 300,000 shares of common stock with an exercise price of $0.08 per share pursuant to the Plan to a consultant for services. The consultant had current information regarding the Company and no general solicitation was used in this offering. For this sale of securities, the Company relied on the exemption from registration available under Section 4(a)(2) of the Securities Act with respect to transactions by an issuer not involving any public offering. No commissions were paid in connection with this issuance of securities.

Other than previously reported, there have been no unregistered sales of equity securities during the nine month period ended September 30, 2016.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

EXHIBIT INDEX

The following documents are being filed with the Commission as exhibits to this Quarterly Report on Form 10-Q.

Exhibit			Description
3.1			Certificate of Incorporation¹
3.2			Bylaws¹
4.1			2015 Stock Option and Stock Bonus Plan²
10.1			Assignment of Patents and Patent Application between the Company and Institut National des Sciences Appliquées de Rouen dated January 5, 2015³
10.2			Settlement and Indemnity Agreement by and between the Company and Standard Bankcorp Inc. and Mark Ralston dated March 2, 2015³
10.3			Royalty Agreement between the Company and The Governors of the University of Alberta, dated April 8, 2015³
10.4			Technology Transfer Agreement between the Company and Grant Young, dated April 22, 2015⁴
10.5			Consulting Agreement between the Company and Clarence E. Smith, dated December 21, 2015⁵
10.6			Consulting Agreement between the Company and Susan M. Woodward, dated December 21, 2015⁵
10.7			Director Consulting Agreement between the Company and Edward P. McDonough, dated December 23, 2015⁵
10.8			ITR Master Contract between the Company and ITR Laboratories Canada Inc., dated April 19, 2016⁶
10.9			Universal Assignment between the Company and Grant Young, dated May 20, 2016⁷
10.10			Collaborative Research Agreement between the Company and the University of British Columbia, dated May 31, 2016⁷
10.11			Secured Line of Credit between the Company and Pleasants County Bank, dated June 16, 2016⁷
31.1			Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002^*
31.2			Certification of the Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002^*
32.1			Certification of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002^**
101.INS			XBRL Instance Document
101.SCH			XBRL Schema Document
101.CAL			XBRL Calculation Linkbase Document
101.DEF			XBRL Definition Linkbase Document
101.LAB			XBRL Label Linkbase Document
101.PRE			XBRL Presentation Linkbase Document

	1.	Incorporated by reference from the Company's registration statement on Form 10-SB filed on June 22, 2001 with the SEC.
	2.	Incorporated by reference from the Company's Quarterly Report on Form 10-Q filed on August 14, 2015 with the SEC.
	3.	Incorporated by reference from the Company's Annual Report on Form 10-K filed on April 14, 2015 with the SEC.
	4.	Incorporated by reference from the Company's Quarterly Report on Form 10-Q filed on May 20, 2015 with the SEC.
	5.	Incorporated by reference from the Company's Annual Report on Form 10-K filed on March 30, 2016 with the SEC.
	6.	Incorporated by reference from the Company's Quarterly Report on Form 10-Q filed on May 16, 2016 with the SEC.
	7.	Incorporated by reference from the Company's Quarterly Report on Form 10-Q filed on August 15, 2016 with the SEC.
	*.	Filed herewith.
	**	Furnished, not filed herewith.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 14, 2016		PROTOKINETIX, INCORPORATED

		By: /s/ Clarence E. Smith
		Clarence E. Smith
		Chief Executive Officer

		By: /s/ Susan M. Woodward
		Susan M. Woodward
		Chief Financial Officer

EX-31.1 2 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Clarence E. Smith, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended September 30, 2016;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2016	/s/ Clarence E. Smith
	Name:	Clarence E. Smith
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 ex31x2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan M. Woodward, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended September 30, 2016;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 14, 2016	/s/ Susan M. Woodward
	Name:	Susan M. Woodward
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 ex32.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ProtoKinetix, Incorporated, (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Clarence E. Smith, Chief Executive Officer and Principal Executive Officer of the Company and Susan M. Woodward, Chief Financial Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

November 14, 2016	/s/ Clarence E. Smith
	Name:	Clarence E. Smith
	Title:	Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

November 14, 2016	/s/ Susan M. Woodward
	Name:	Susan M. Woodward
	Title:	Chief Financial Officer (Principal Financial Officer)

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-101.INS 5 pktx-20160930.xml XBRL INSTANCE DOCUMENT 0001128189 2016-01-01 2016-09-30 0001128189 2015-09-30 0001128189 2016-09-30 0001128189 2015-12-31 0001128189 2015-01-01 2015-09-30 0001128189 us-gaap:CommonStockMember 2015-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001128189 us-gaap:RetainedEarningsMember 2015-12-31 0001128189 us-gaap:CommonStockMember 2016-01-01 2016-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-09-30 0001128189 us-gaap:RetainedEarningsMember 2016-01-01 2016-09-30 0001128189 us-gaap:CommonStockMember 2016-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2016-09-30 0001128189 us-gaap:RetainedEarningsMember 2016-09-30 0001128189 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001128189 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001128189 pktx:CommonStockIssuableMember 2015-12-31 0001128189 pktx:CommonStockIssuableMember 2016-09-30 0001128189 pktx:ClarenceSmithCEOMember 2015-12-31 0001128189 us-gaap:WarrantMember 2016-01-01 2016-09-30 0001128189 us-gaap:WarrantMember 2015-12-31 0001128189 us-gaap:WarrantMember 2016-09-30 0001128189 pktx:ClarenceSmithCEOMember 2016-09-30 0001128189 us-gaap:StockOptionMember 2016-01-01 2016-09-30 0001128189 us-gaap:StockOptionMember 2015-12-31 0001128189 us-gaap:StockOptionMember 2016-09-30 0001128189 pktx:Date1Member 2016-09-30 0001128189 pktx:Date2Member 2016-09-30 0001128189 pktx:Date3Member 2016-09-30 0001128189 pktx:Date4Member 2016-09-30 0001128189 2015-07-01 2015-09-30 0001128189 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001128189 pktx:Date7Member 2016-09-30 0001128189 pktx:Date6Member 2016-09-30 0001128189 pktx:WarrantOneMember 2016-09-30 0001128189 pktx:WarrantOneMember 2016-01-01 2016-09-30 0001128189 pktx:WarrantTwoMember 2016-09-30 0001128189 pktx:WarrantTwoMember 2016-01-01 2016-09-30 0001128189 2014-12-31 0001128189 2014-01-01 2014-12-31 0001128189 2015-01-01 2015-12-31 0001128189 pktx:MarchMember 2016-01-01 2016-09-30 0001128189 pktx:FebruaryMember 2015-01-01 2015-09-30 0001128189 pktx:Date9Member 2016-09-30 0001128189 us-gaap:OptionMember 2016-09-30 0001128189 us-gaap:DirectorMember 2015-01-01 2015-09-30 0001128189 2016-07-01 2016-09-30 0001128189 2016-11-14 0001128189 pktx:JuneMember 2015-01-01 2015-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure --12-31 pktx 2016-09-30 No Smaller Reporting Company No 10-Q false 2016 ProtoKinetix, Inc. 0001128189 Yes Q3

0.0000053

400000000

255993

449752

75599

70260

180394

379492

91429

397

8023

40386

45388

327

1359

1210

1159

255993

449752

215607

404364

1159

27498836

-27095631

1210

28459913

-28245516

-27095631

28459913

27498836

226202433

216602433

226202433

216602433

226202433

84000

3840000

192000

0.05

161750

192000

0.08

1250000

90000

23500

40386

45388

163526

88965

371072

317

227452433

574128

290728

117485

199365

355089

101970

29850

174957

147977

219848

49325

8780

39664

3969

70441

105468

23119

17341

65000

15000

2250

750

1149885

786983

234779

432077

7272

-1149885

-779711

-1149885

-227507

-432077

-0.01

-0.00

219242214

194626737

202076618

222088754

1100000

100000

1000000

100000

7000

6999

574128 574128

9500000

380000

379950

0 8780 574128 290728 7000 69000

-654518

-386041

-5002

35557

91032

637

-8023

2486

7589

40000

-7589

-40000

380000

652500

-63250

380000

589250

-282107

163209

0 25000 0 25000 7000 69000 0 100000 0 25000

ProtoKinetix, Inc. (the "Company"), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.   The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins ("AFGP") or anti-aging glycoproteins, trademarked AAGP.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).   A Cease Trade Order ("CTO") was issued in respect of the Company's securities by the British Columbia Securities Commission ("BCSC") on May 9, 2013 based on the Company's failure to file annual financial statements for the year ended December 31, 2012 by the deadline of April 1, 2013. The Company has since completed all of the required filings for annual and interim periods and received a full Revocation Order from the BCSC during the year ended December 31, 2015.   During the nine month period ended September 30, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the BCSC.   The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.   The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2016.  These factors raise substantial doubt about the Company's ability to continue as a going concern.   The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans.   The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Basis of Presentation   The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K, filed March 30, 2016, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.   Use of Estimates   Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.   Cash   Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.   Fair Value of Financial Instruments   Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:   Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   Level 1 inputs are used to measure cash. At September 30, 2016 there were no other assets or liabilities subject to additional disclosure.   Income Taxes   The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.   Intangible assets – patent and patent application costs   The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.   As at September 30, 2016, the Company does not hold any intangible assets with indefinite lives.   Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.   Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.   Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2016.   Research and Development Costs   Research and development costs are expensed as incurred.   Loss per Share and Potentially Dilutive Securities   Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 28,600,000 stock options (September 30, 2015 – 14,600,000) and 6,500,000 warrants (September 30, 2015 – 12,262,500) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.   Share-Based Compensation   The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.   The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.   The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 "Stock-Based Transactions with Nonemployees", which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.   Common stock   Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete.   Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.   Related Party Transactions   A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.   Recent Accounting Pronouncements   In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.     Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company is reviewing this update to determine the impact it will have on its financial statements.     Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.     Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.     Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy is effective December 16, 2016. The Company is evaluating this guidance and believes it will have little impact on the presentation of its financial statements.     Accounting Standards Update 2015-02 - Consolidation (Topic 810) - Amendments to the Consolidation Analysis. This update provides guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard which has little impact on the presentation of its financial statements.     Accounting Standards Update 2015-01 - Income Statement—Extraordinary and Unusual Items (Subtopic 225-20). This Update is part of an initiative to reduce complexity in accounting standards (the Simplification Initiative). This Update eliminates from GAAP the concept of extraordinary items. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard.

Accounts receivable consists of refundable sales tax paid on purchases made in Canada.

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the "Patent Assignment") with the Institut National des Sciences Appliquees de Rouen ("INSA") for the assignment of certain patents and all rights associated therewith (the "Patents"). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period ended September 30, 2016, the Company recorded $2,250 (September 30, 2015 - $nil) in amortization expense associated with the Patents.   During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the "Patent Application Rights").  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company incurred an additional $11,933 in direct costs relating to the Patent Application Rights, $5,173 of which were incurred during the nine month period ended September 30, 2016.   The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.   During the nine month period ended September 30, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells" (the "New Patent Application Rights").  In exchange for the New Patent Application Rights, the Company agreed to pay $1.00 (paid).  The Company incurred $2,416 in direct costs relating to the New Patent Application Rights.   No amortization was recorded on the Patent Application Rights or the New Patent Application Rights to September 30, 2016.

Convertible Note Payable   On July 1, 2011, the Company executed a loan agreement under which the Company issued to a corporation an 8% convertible promissory note in exchange for $300,000.  The note holder had the right to demand payment of outstanding principal and interest at any time with a 30-day grace period.  The note was due and payable no later than June 30, 2016, and was convertible into shares of the Company's common stock at $0.025 per share.  No beneficial conversion feature was applicable to this convertible note.   During the year ended December 31, 2014, the Company and the corporation commenced discussions in regards to the settlement of the convertible note through extinguishment. A settlement agreement was finalized during the year ended December 31, 2015, but the Company has accounted for the transaction as at December 31, 2014. The settlement agreement stipulated that the convertible note plus accrued interest of $84,000 (included in accounts payable and accrued liabilities as at December 31, 2014) was to be settled through the issuance of 3,840,000 shares of the Company's common stock. The fair value of the shares was determined to be $192,000 ($0.05 per share) and the Company recognized a gain on settlement in the amount of $192,000 as at December 31, 2014.   The settlement agreement also stipulated the payment of $161,750 to the corporation to settle other amounts included in accounts payable and accrued liabilities and short-term loans, all of which had been paid as at December 31, 2015.   On June 17, 2014, the Company executed a loan agreement under which the Company issued an 8% convertible promissory note in exchange for an initial amount of $10,000, with the ability to be increased to $100,000, to the Company`s President and CEO.  During the year ended December 31, 2014, additional amounts totaling $90,000 were advanced, $23,500 of which was paid directly to settle certain short-term loans outstanding. The note holder had the right to demand payment of outstanding principal and interest at any time with a 30-day grace period.  The note was due and payable no later than December 31, 2015, and was convertible into shares of the Company's common stock at $0.25 per share.  No beneficial conversion feature was applicable to this convertible note.  On July 1, 2015, the Company`s board of directors approved an adjustment to the conversion price from $0.25 to $0.08.  During the year ended December 31, 2015, the Company issued 1,250,000 shares of the Company's common stock at the adjusted conversion price of $0.08 per share to settle the promissory note. A gain of $7,272 was recognized associated with interest forgiven on the note.   Credit Facility   On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia.  Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly.  The Company's President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, "Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells". As at September 30, 2016, the balance outstanding was $nil.

During the nine month periods ended September 30, 2016 and 2015, the Company issued shares of common stock for services and other value rendered as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">   2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 58%; padding-bottom: 1.5pt; text-align: justify">March 2016</td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt">$</td> <td style="vertical-align: bottom; width: 11%; padding-bottom: 1.5pt; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">   2015</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 58%; text-align: justify">February 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">1,000,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">0.04</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">40,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">June 2015</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">$</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">1,100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">47,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the "Plan").  The Board of Directors adopted this plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.   Under the Plan, the lesser of: (i) 20,000,000 shares; or (ii) 10% of the total number of the Company's common shares outstanding are reserved to be issued upon the exercise of options or the grant of stock bonuses.  As such, the Plan is subject to an absolute cap of 20,000,000 shares.  The Plan includes two types of options; options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options, and options which are not intended to qualify as incentive options are referred to as non-qualified options.   As of September 30, 2016, 16,600,000 options and 2,000,000 shares of common stock have been granted under the Plan.   The Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors.  In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted.  The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the Plan.  The committee may determine the purchase price of the shares of common stock covered by each option and determine the fair market value per share.  The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the Plan.  The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the Plan.   In the event that a change, such as a stock split, is made in the Company's capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option.  The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock.  Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the Plan shall terminate as of a date fixed by the committee.   The exercise price of any option granted under the Plan must be no less than 100% of the "fair market value" of the Company's common stock on the date of grant.  Any incentive stock option granted under the Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant.   The exercise price of an option may be paid in cash, in shares of the Company's common stock or other property having a fair market value equal to the exercise price of the option, or in a combination of cash, shares, other securities and property.  The committee determines whether or not property other than cash or common stock may be used to purchase the shares underlying an option and shall determine the value of the property received.   Stock option transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Stock Options</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Fair Value</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid"> Weighted Average  Remaining Life</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">(Years)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 51%">Outstanding, December 31, 2015</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">14,600,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.05</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.03</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 10%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>     Options granted</td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">0.05</td> <td nowrap="nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid; padding-left: 10pt">Options expired</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid">)</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">Outstanding, September 30, 2016</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">28,600,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.06</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.04</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2.92</td></tr> </table>     The fair values of the stock options granted during the nine month periods ended September 30, 2016 and 2015 were estimated using the Black-Scholes Option Pricing Model.  The weighted average assumptions used in the pricing model for these options are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">September 30, 2015</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">September 30, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; text-indent: 0.05in">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">0.81</td> <td nowrap="nowrap" style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">0.56</td> <td nowrap="nowrap" style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Expected stock price volatility</td> <td> </td> <td> </td> <td style="text-align: right">125.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">125.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Expected forfeiture rate</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; text-indent: 0.05in">Expected life</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right">4.81 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right">3.94 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> </table>   The following non-qualified stock options were outstanding and exercisable at September 30, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Expiry date</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Outstanding</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Exercisable</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 67%">February 25, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">0.04</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">2,000,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">-</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 24, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 25, 2020</td> <td> </td> <td> </td> <td style="text-align: right">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 28, 2020</td> <td> </td> <td> </td> <td style="text-align: right">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>June 30, 2017</td> <td> </td> <td> </td> <td style="text-align: right">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>June 30, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid">December 31, 2019</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.08</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">15,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,250,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">28,600,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">22,850,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> </table>   As at September 30, 2016, the aggregate intrinsic value of the Company's stock options is $398,000 (December 31, 2015 – $350,000). The weighted average fair value of stock options granted during the nine month period ended September 30, 2016 is $0.05 (2015 - $0.03). Warrant transactions for the nine month period ended September 30, 2016 are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Warrants</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 78%; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 8%; text-align: right">8,700,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 8%; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify">     Expired</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">(2,200,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid">)</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, September 30, 2016</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table>   The following warrants were outstanding and exercisable as at September 30, 2016:     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="width: 35%; border-bottom: black 1.5pt solid">   Number of Warrants</td> <td style="width: 32%; border-bottom: black 1.5pt solid">   Exercise Price ($)</td> <td style="width: 32%; border-bottom: black 1.5pt solid">   Expiry Date</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">500,000</td> <td style="text-align: right">           0.25</td> <td style="text-align: right">November 8, 2018</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,000,000</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td style="border-bottom: black 1.5pt solid; text-align: right">April 22, 2020</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td></tr> </table>

The Company is authorized to issue 400,000,000 (December 31, 2015 – 400,000,000) shares of $0.0000053 par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2016 (December 31, 2015 - $nil).   During the nine month period ended September 30, 2016, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%; font: 12pt Times New Roman, Times, Serif">a)</td> <td style="width: 95%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Issued 100,000 shares of common stock with a fair value of $7,000 ($0.07 per share) pursuant to a consulting agreement entered into on March 1, 2015 (Note 11(b)).</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%; font: 12pt Times New Roman, Times, Serif">b)</td> <td style="width: 95%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Issued 4,150,000 shares of common stock to investors (one of which was the President and CEO of the Company) at $0.04 per share for gross proceeds of $166,000.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%; font: 12pt Times New Roman, Times, Serif">c)</td> <td style="width: 95%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Issued 5,350,000 shares of common stock to investors (one of which was the President and CEO of the Company) at $0.04 per share for gross proceeds of $214,000.</td></tr> </table>

During the nine month period ended September 30, 2015, the Company: <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">a)</td><td style="text-align: justify">Entered into a directorship agreement effective February 25, 2015 with a newly appointed director of the Company. Pursuant to the agreement, the director was issued 1,000,000 shares of common stock as an engagement fee and was entitled to a compensatory service fee. The director was also entitled to 1,000,000 stock options on signing exercisable into common shares of the Company for a period of 3 years at a price of $0.05 per share.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"></td><td style="text-align: justify">During the nine month period ended September 30, 2015, the director provided $8,780 in contributed services, which were recorded as professional fees against additional paid-in capital.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">b)</td><td style="text-align: justify">Entered into a consulting agreement dated March 30, 2015 (effective January 1, 2015) with the Company's President and CEO whereby he was compensated at a nominal amount of $1 for services through to December 31, 2015. The agreement also stipulates a termination fee that would pay the Company's President and CEO $100,000 if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 plus 2.5% of the aggregate transaction value of the change of control.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">c)</td><td style="text-align: justify">Entered into a consulting agreement dated March 30, 2015 (effective January 1, 2015) with the Company's CFO whereby she was compensated at a monthly fee of $4,000 for services through to December 31, 2018 ($4,000 per month for fiscal 2015, then increased by not less than 5% each year thereafter). A total of $36,000 was paid or accrued to the Company's CFO during the nine month period ended September 30, 2015.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"></td><td style="text-align: justify">Shewas also entitled (as of February 26, 2015) to 4,000,000 stock options exercisable into common shares of the Company for a period of 5 years at a price of $0.04 per share. The options vested monthly in tranches of 400,000 over 10 months. She was also entitled to an additional 2,000,000 stock options exercisable for a period of 2 years at a price of $0.04 per share that will vest only upon a change in control. If terminated without cause, the agreement also stipulates a termination fee that would pay the Company's CFO three times her monthly consulting fee in effect as of the date of termination or if terminated without cause after January 1, 2016, six times her monthly consulting fee in effect as of the date of termination. In the case of termination upon a change of control event, the termination fee would be equal to two times the amount that she would receive as if terminated without cause.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">d)</td><td style="text-align: justify">Entered into a directorship agreement effective July 1, 2015 with a newly appointed director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options on signing exercisable into common shares of the Company for a period of 2 years at a price of $0.10 per share. The options vested in monthly installments of 166,666 options beginning July 31, 2015 with the final 166,670 options vesting on December 31, 2015.</td> </tr></table> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%; font: 12pt Times New Roman, Times, Serif">e)</td> <td style="width: 95%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Recognized $137,810 in share-based compensation associated with stock options granted to key management personnel.</td></tr> </table> During the nine month period ended September 30, 2016, the Company: <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">a)</td><td style="text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 with the Company's President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company's President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control.  In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement.  Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2016..</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">b)</td><td style="text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 with the Company's CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016.  The agreement also stipulates a termination fee that would pay the Company's CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event.  Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2016. A total of $54,000 was paid or accrued to the Company's CFO during the nine month period ended September 30, 2016 and is included in professional fees.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">c)</td><td style="text-align: justify">Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2016.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">d)</td><td style="text-align: justify">Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.</td> </tr></table>   As at September 30, 2016 and December 31, 2015, the following amounts are due to related parties:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">September 30, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">Clarence Smith (CEO)</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right">1,359</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right">327</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

As at September 30, 2016, the Company has the following commitments:   <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">a)</td><td style="text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 whereby the Company would pay the consultant $7,000 per month for providing research and development services.  Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options vest in equal instalments on a quarterly basis beginning March 31, 2016.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"> </td><td style="text-align: justify"> </td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">b)</td><td style="text-align: justify">Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year for providing public relations services. The consultant was also entitled to 400,000 shares of common stock, which were issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (100,000 shares issued during the nine month period ended September 30, 2016 (Note 9)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10 for a period of 5 years. The stock options vested at the rate of 25% every 3 months over the term of the agreement.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"> </td><td style="text-align: justify"> </td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">c)</td><td style="text-align: justify">Entered into a royalty agreement with the Governors of the University of Alberta (the "University") whereby the University had developed certain intellectual property (the "Additional Patent Rights") in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the "Royalty") derived from products arising from the Patent Rights. The Company will have the right and option for two years from the earlier of September 1, 2015 or the first date that the University publishes its research related to the Additional Patent Rights to buy out all of the University's Royalty for consideration of the aggregate sum of CDN $5,000,000.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"> </td><td style="text-align: justify"> </td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">d)</td><td style="text-align: justify">Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year for providing research and development services.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"> </td><td style="text-align: justify"> </td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">e)</td><td style="text-align: justify">Entered into a Collaborative Research Agreement (the "CREA") effective May 31, 2016 with The University of British Columbia ("UBC") for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and will be required to pay an additional CAD $201,500 within 12 months from the effective date of the CREA in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days' written notice. As at September 30, 2016, a total of $87,132 is included in prepaid expenses and deposits.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left"> </td><td style="text-align: justify"> </td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0pt"></td><td style="width: 20pt; text-align: left">f)</td><td style="text-align: justify">Entered into a series of Study Contracts (the "Contracts") with ITR Laboratories Canada ("ITR") effective April 19, 2016 whereby ITR will provide research services to the Company. Pursuant to the terms of the Contracts, 50% of the total cost of the Contracts was payable on authorization. The total fees associated with the Contracts is CAD $60,600 and as at September 30, 2016, the Company owed  CAD $18,000 ($12,310).</td> </tr></table>   The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, "Report of Foreign Bank and Financial Accounts" ("FBARs"). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities.  The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements.  No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

Subsequent to the nine month period ended September 30, 2016, the Company:   Entered into a consulting agreement for business development services effective October 1, 2016.  The consultant was granted 300,000 stock options exercisable into common shares of the Company at a price of $0.08 per share for a period of two years.  The options will vest in monthly installments of 100,000 options beginning October 31, 2016 with the final 100,000 options vesting on December 31, 2016.   Issued 1,250,000 shares of common stock to the President and CEO of the Company at $0.04 per share for gross proceeds of $50,000.00.

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K, filed March 30, 2016, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:   Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   Level 1 inputs are used to measure cash. At September 30, 2016 there were no other assets or liabilities subject to additional disclosure.

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 "Income Taxes."  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.   As at September 30, 2016, the Company does not hold any intangible assets with indefinite lives.   Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.   Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.   Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2016.

Research and development costs are expensed as incurred.

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 28,600,000 stock options (September 30, 2015 – 14,600,000) and 6,500,000 warrants (September 30, 2015 – 12,262,500) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.   The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance.   The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 "Stock-Based Transactions with Nonemployees", which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete.   Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">   2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 58%; padding-bottom: 1.5pt; text-align: justify">March 2016</td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt">$</td> <td style="vertical-align: bottom; width: 11%; padding-bottom: 1.5pt; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; width: 11%; border-bottom: black 1.5pt solid; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">   2015</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 58%; text-align: justify">February 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 11%; text-align: right">1,000,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">0.04</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 11%; text-align: right">40,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">June 2015</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt">$</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">1,100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">47,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Stock Options</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Fair Value</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid"> Weighted Average  Remaining Life</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">(Years)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 51%">Outstanding, December 31, 2015</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">14,600,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.05</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">0.03</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 10%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>     Options granted</td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">0.05</td> <td nowrap="nowrap"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid; padding-left: 10pt">Options expired</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid">)</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">Outstanding, September 30, 2016</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">28,600,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.06</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.04</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">2.92</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">September 30, 2015</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">September 30, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 78%; text-indent: 0.05in">Risk-free interest rate</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">0.81</td> <td nowrap="nowrap" style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">0.56</td> <td nowrap="nowrap" style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Expected stock price volatility</td> <td> </td> <td> </td> <td style="text-align: right">125.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">125.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Expected forfeiture rate</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td> <td> </td> <td> </td> <td style="text-align: right">0.00</td> <td nowrap="nowrap">%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; text-indent: 0.05in">Expected life</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right">4.81 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: right">3.94 years</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Expiry date</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Outstanding</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Exercisable</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 67%">February 25, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">0.04</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">2,000,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right">-</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 24, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 25, 2020</td> <td> </td> <td> </td> <td style="text-align: right">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 28, 2020</td> <td> </td> <td> </td> <td style="text-align: right">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>June 30, 2017</td> <td> </td> <td> </td> <td style="text-align: right">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>June 30, 2018</td> <td> </td> <td> </td> <td style="text-align: right">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid">December 31, 2019</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.08</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">15,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,250,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">28,600,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">22,850,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Warrants</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 78%; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 8%; text-align: right">8,700,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 8%; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: justify">     Expired</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">(2,200,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid">)</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, September 30, 2016</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="width: 35%; border-bottom: black 1.5pt solid">   Number of Warrants</td> <td style="width: 32%; border-bottom: black 1.5pt solid">   Exercise Price ($)</td> <td style="width: 32%; border-bottom: black 1.5pt solid">   Expiry Date</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td> </td> <td style="text-align: right">500,000</td> <td style="text-align: right">           0.25</td> <td style="text-align: right">November 8, 2018</td></tr> <tr style="vertical-align: top; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">6,000,000</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td style="border-bottom: black 1.5pt solid; text-align: right">April 22, 2020</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">September 30, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">December 31, 2015</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 36%; border-bottom: black 1.5pt solid">Clarence Smith (CEO)</td> <td style="vertical-align: top; width: 34%; border-bottom: black 1.5pt solid">Accounts payable and accrued liabilities</td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: right">1,359</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; width: 12%; border-bottom: black 1.5pt solid; text-align: right">327</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td></tr> </table>

6500000

12262500

28600000

14600000

0.07 .07 .04 .07

7000

47000

7000

40000

7000

28600000

8700000

6500000

14600000

28600000

2000000

1000000

4000000

5000000

1000000

600000

15000000

1000000

.11

.05

.06

0.04

0.05

0.04

0.1

0.08

.08

.10

.03

.04

.05

.03

.05

.03

P2Y11M1D

.0081

.0056

0.00

1.2500

0.00 0.00

P4Y9M22D

P3Y11M8D

22850000

1000000

4000000

5000000

1000000

600000

11250000

2200000

.10

6500000

500000

6000000

.25 .10 November 8, 2018 April 22, 2020

54000

36000

2000000

16600000

398000

350000

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.     Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company is reviewing this update to determine the impact it will have on its financial statements.     Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.     Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.     Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy is effective December 16, 2016. The Company is evaluating this guidance and believes it will have little impact on the presentation of its financial statements.     Accounting Standards Update 2015-02 - Consolidation (Topic 810) - Amendments to the Consolidation Analysis. This update provides guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard which has little impact on the presentation of its financial statements.     Accounting Standards Update 2015-01 - Income Statement—Extraordinary and Unusual Items (Subtopic 225-20). This Update is part of an initiative to reduce complexity in accounting standards (the Simplification Initiative). This Update eliminates from GAAP the concept of extraordinary items. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard.

EX-101.SCH 6 pktx-20160930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Basis of Presentation - Going Concern Uncertainties link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Convertible Note Payable and Credit Facility link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Common Shares Issued for Services link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Stock Options link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Related Party Transactions and Balances link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Commitments and Contingency link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 6. Common Shares Issued for Services (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 7. Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 8. Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 10. Related Party Transactions and Balances (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 4. Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 5. Convertible Note Payable and Credit Facility (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 6. Common Shares Issued for Services (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 7. Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 7. Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 7. Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 7. Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 8. Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 8. Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 9. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 10. Related Party Transactions and Balances (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 10. Related Party Transactions and Balances (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pktx-20160930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 pktx-20160930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 pktx-20160930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock Statement, Equity Components [Axis] Additional paid-in capital Accumulated Deficit Warrant Antidilutive Securities [Axis] Common Stock Issuable Clarence Smith (CEO) Related Party [Axis] Award Type [Axis] Stock options February 25, 2017 Exercise Price Range [Axis] February 24, 2018 February 25, 2020 February 28, 2020 June 30, 2017 June 30, 2018 Warrant One Warrant Two March 2016 February 2015 December 31, 2019 Options Director Title of Individual [Axis] June 2015 Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Trading Symbol Current Fiscal Year End Date Entity Filer Category Entity Voluntary Filers Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable (Note 3) Prepaid expenses and deposits (Note 11) Total current assets Intangible assets (Note 4) Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued liabilities (Note 10) Total current liabilities Stockholders' Equity Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 226,202,433 and 216,602,433 shares issued and outstanding as at September 30, 2016 and December 31, 2015 respectively (Note 9) Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Common Stock, Par Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] EXPENSES Amortization - intangible assets (Note 4) Consulting fees (Note 10) General and administrative Interest Professional fees (Note 10) Research and development Share-based compensation (Note 10) Total OTHER ITEMS Gain on settlement of short-term loan (Note 5) Foreign exchange gain (loss) Net loss for the period Loss per common share (basic and diluted) Weighted average number of common shares outstanding (basic and diluted) Statement [Table] Statement [Line Items] Equity Components [Axis] Beginning Balance, Shares Beginning Balance, Amount Issuance of common stock for services, shares Issuance of common stock for services, amount Fair value of compensatory options issued Issuance of common stock pursuant to private placement offering, shares Issuance of common stock pursuant to private placement offering, amount Net loss for the period Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] CASH FLOWS USED IN OPERATING ACTIVITIES Adjustments to reconcile net loss to cash used in operating activities: Amortization - intangible assets Issuance and amortization of common stock for services Fair value of compensatory options granted Contribution of services Gain on settlement of short term loans Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and deposits Accounts payable and accrued liabilities Net cash used in operating activities CASH FLOWS USED IN INVESTING ACTIVITIES Purchase of Intangible assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Short-term loan repayments Issuance of common stock for cash Net cash from financing activities Net change in cash Cash, beginning of period Cash, end of period Cash paid for interest Cash paid for income taxes Supplementary information - non-cash transactions: Common stock issued for consulting services Common stock returned to treasury Common stock issued for past subscriptions Common stock issued to settle promissory note Fair value of warrants issued for intangible asset Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation - Going Concern Uncertainties Accounting Policies [Abstract] Summary of Significant Accounting Policies Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Accounts Receivable Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Convertible Note Payable and Credit Facility Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Common Shares Issued for Services Stock Options Stock Options Warrants Warrants Stockholders' Equity Note [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions and Balances Commitments and Contingencies Disclosure [Abstract] Commitments and Contingency Subsequent Events [Abstract] Subsequent Events Basis of Presentation Use of Estimates Cash Fair Value of Financial Instruments Income Taxes Intangible assets - patent and patent application costs Research and Development Costs Loss per Share and Potentially Dilutive Securities Share-Based Compensation Common stock Related Party Transactions Recent Accounting Pronouncements Schedule of Stock Incentive Plan, Issuances Stock Options Tables Schedule of Share-based Compensation, Stock Options, Activity Schedule of valuation assumptions for options Schedule of options by exercise price Warrants Tables Schedule of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of related party transactions Antidilutive Securities Excluded from Computation of Earnings Per Share Amortization expense Accrued interest include accounts payable and accrued liabilities Issuance of common stock to settle Fair value of the shares Fair value of the shares per share Gain on settlement on loan Stipulated the payment Common stock conversion shares Common stock conversion price per share Short-term loans outstanding Advances Number of Shares Value per Share Total Outstanding, beginning Options granted Options expired Outstanding, ending Weighted Average Exercise Price beginning Weighted Average Exercise Price, granted Weighted Average Exercise Price, expired Weighted Average Exercise Price ending Weighted Average Fair Value, beginning Weighted Average Fair Value, granted Weighted Average Fair Value, expired Weighted Average Fair Value, ending Weighted Average Remaining Life (Years) EX-101.PRE 10 pktx-20160930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Nov. 14, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ProtoKinetix, Inc.
Entity Central Index Key	0001128189
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Trading Symbol	pktx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		227,452,433
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2016

XML 12 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current Assets
Cash	$ 88,965	$ 371,072
Accounts receivable (Note 3)	0	8,023
Prepaid expenses and deposits (Note 11)	91,429	397
Total current assets	180,394	379,492
Intangible assets (Note 4)	75,599	70,260
Total assets	255,993	449,752
Current Liabilities
Accounts payable and accrued liabilities (Note 10)	40,386	45,388
Total current liabilities	40,386	45,388
Stockholders' Equity
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 226,202,433 and 216,602,433 shares issued and outstanding as at September 30, 2016 and December 31, 2015 respectively (Note 9)	1,210	1,159
Additional paid-in capital	28,459,913	27,498,836
Accumulated deficit	(28,245,516)	(27,095,631)
Total stockholders' equity	215,607	404,364
Total liabilities and stockholders' equity	$ 255,993	$ 449,752

XML 13 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Common Stock, Shares, Issued	226,202,433	216,602,433
Common Stock, Shares, Outstanding	226,202,433	216,602,433

XML 14 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
EXPENSES
Amortization - intangible assets (Note 4)	$ 750	$ 0	$ 2,250	$ 0
Consulting fees (Note 10)	0	15,000	0	65,000
General and administrative	17,341	23,119	70,441	105,468
Interest	0	0	0	3,969
Professional fees (Note 10)	39,664	49,325	147,977	219,848
Research and development	174,957	29,850	355,089	101,970
Share-based compensation (Note 10)	199,365	117,485	574,128	290,728
Total	(432,077)	(234,779)	(1,149,885)	(786,983)
OTHER ITEMS
Gain on settlement of short-term loan (Note 5)	0	7,272	0	7,272
Net loss for the period	$ (432,077)	$ (227,507)	$ (1,149,885)	$ (779,711)
Loss per common share (basic and diluted)	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.00)
Weighted average number of common shares outstanding (basic and diluted)	222,088,754	202,076,618	219,242,214	194,626,737

XML 15 R5.htm IDEA: XBRL DOCUMENT

STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - 9 months ended Sep. 30, 2016 - USD ($)	Common Stock	Common Stock Issuable	Additional paid-in capital	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2015	216,602,433	0
Beginning Balance, Amount at Dec. 31, 2015	$ 1,159	$ 0	$ 27,498,836	$ (27,095,631)	$ 404,364
Issuance of common stock for services, shares	100,000
Issuance of common stock for services, amount	$ 1		6,999		7,000
Fair value of compensatory options issued			574,128		574,128
Issuance of common stock pursuant to private placement offering, shares	9,500,000
Issuance of common stock pursuant to private placement offering, amount	$ 50		379,950		380,000
Net loss for the period				(1,149,885)	(1,149,885)
Ending Balance, Shares at Sep. 30, 2016	226,202,433	0
Ending Balance, Amount at Sep. 30, 2016	$ 1,210	$ 0	$ 28,459,913	$ (28,245,516)	$ 215,607

XML 16 R6.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$ (1,149,885)	$ (779,711)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization - intangible assets	2,250	0
Issuance and amortization of common stock for services	7,000	69,000
Fair value of compensatory options granted	574,128	290,728
Contribution of services	0	8,780
Gain on settlement of short term loans	0	(7,272)
Changes in operating assets and liabilities:
Accounts receivable	8,023	(2,486)
Prepaid expenses and deposits	(91,032)	(637)
Accounts payable and accrued liabilities	(5,002)	35,557
Net cash used in operating activities	(654,518)	(386,041)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of Intangible assets	(7,589)	(40,000)
Net cash used in investing activities	(7,589)	(40,000)
CASH FLOWS FROM FINANCING ACTIVITIES
Short-term loan repayments	0	(63,250)
Issuance of common stock for cash	380,000	652,500
Net cash from financing activities	380,000	589,250
Net change in cash	(282,107)	163,209
Cash, beginning of period	371,072	317
Cash, end of period	88,965	163,526
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplementary information - non-cash transactions:
Common stock issued for consulting services	7,000	69,000
Common stock returned to treasury	0	25,000
Common stock issued for past subscriptions	0	25,000
Common stock issued to settle promissory note	0	100,000
Fair value of warrants issued for intangible asset	$ 0	$ 25,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

1. Basis of Presentation - Going Concern Uncertainties

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation - Going Concern Uncertainties

During the nine month period ended September 30, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the BCSC.

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

XML 18 R8.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2016

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Cash

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At September 30, 2016 there were no other assets or liabilities subject to additional disclosure.

Income Taxes

Intangible assets – patent and patent application costs

As at September 30, 2016, the Company does not hold any intangible assets with indefinite lives.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Share-Based Compensation

Common stock

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

Recent Accounting Pronouncements

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT

3. Accounts Receivable	9 Months Ended
3. Accounts Receivable	Sep. 30, 2016
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Accounts Receivable	Accounts receivable consists of refundable sales tax paid on purchases made in Canada.

XML 20 R10.htm IDEA: XBRL DOCUMENT

4. Intangible Assets

9 Months Ended

Sep. 30, 2016

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.

No amortization was recorded on the Patent Application Rights or the New Patent Application Rights to September 30, 2016.

XML 21 R11.htm IDEA: XBRL DOCUMENT

5. Convertible Note Payable and Credit Facility

9 Months Ended

Sep. 30, 2016

Debt Disclosure [Abstract]

Convertible Note Payable and Credit Facility

Convertible Note Payable

Credit Facility

XML 22 R12.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Shares Issued for Services

During the nine month periods ended September 30, 2016 and 2015, the Company issued shares of common stock for services and other value rendered as follows:

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

2015	Number of Shares		Value per Share		Total

February 2015		1,000,000	$	0.04	$	40,000
June 2015		100,000	$	0.07	$	7,000
		1,100,000			$	47,000

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 23 R13.htm IDEA: XBRL DOCUMENT

7. Stock Options

9 Months Ended

Sep. 30, 2016

Stock Options

Stock Options

As of September 30, 2016, 16,600,000 options and 2,000,000 shares of common stock have been granted under the Plan.

Stock option transactions are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2015		14,600,000			0.05		0.03
Options granted		15,000,000			0.08		0.05
Options expired		(1,000,000	)		0.10		0.03
Outstanding, September 30, 2016		28,600,000			0.06		0.04	2.92

	September 30, 2015			September 30, 2016
Risk-free interest rate		0.81	%		0.56	%
Dividend yield		0.00	%		0.00	%
Expected stock price volatility		125.00	%		125.00	%
Expected forfeiture rate		0.00	%		0.00	%
Expected life	4.81 years			3.94 years

The following non-qualified stock options were outstanding and exercisable at September 30, 2016:

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
	$
February 25, 2017		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2017		0.10		1,000,000		1,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		11,250,000
				28,600,000		22,850,000

XML 24 R14.htm IDEA: XBRL DOCUMENT

8. Warrants

9 Months Ended

Sep. 30, 2016

Warrants

Warrants

Warrant transactions for the nine month period ended September 30, 2016 are summarized as follows:

	Number of Warrants			Weighted Average Exercise Price
Balance, December 31, 2015		8,700,000		$	0.11
Expired		(2,200,000	)		0.10
Balance, September 30, 2016		6,500,000		$	0.11

The following warrants were outstanding and exercisable as at September 30, 2016:

Number of Warrants	Exercise Price ($)	Expiry Date
500,000	0.25	November 8, 2018
6,000,000	0.10	April 22, 2020
6,500,000

XML 25 R15.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Stockholders' Equity Note [Abstract]

Stockholders' Equity

During the nine month period ended September 30, 2016, the Company:

a)	Issued 100,000 shares of common stock with a fair value of $7,000 ($0.07 per share) pursuant to a consulting agreement entered into on March 1, 2015 (Note 11(b)).

b)	Issued 4,150,000 shares of common stock to investors (one of which was the President and CEO of the Company) at $0.04 per share for gross proceeds of $166,000.

c)	Issued 5,350,000 shares of common stock to investors (one of which was the President and CEO of the Company) at $0.04 per share for gross proceeds of $214,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances

9 Months Ended

Sep. 30, 2016

Related Party Transactions and Balances

During the nine month period ended September 30, 2015, the Company:

During the nine month period ended September 30, 2015, the director provided $8,780 in contributed services, which were recorded as professional fees against additional paid-in capital.

Shewas also entitled (as of February 26, 2015) to 4,000,000 stock options exercisable into common shares of the Company for a period of 5 years at a price of $0.04 per share. The options vested monthly in tranches of 400,000 over 10 months. She was also entitled to an additional 2,000,000 stock options exercisable for a period of 2 years at a price of $0.04 per share that will vest only upon a change in control. If terminated without cause, the agreement also stipulates a termination fee that would pay the Company's CFO three times her monthly consulting fee in effect as of the date of termination or if terminated without cause after January 1, 2016, six times her monthly consulting fee in effect as of the date of termination. In the case of termination upon a change of control event, the termination fee would be equal to two times the amount that she would receive as if terminated without cause.

e)	Recognized $137,810 in share-based compensation associated with stock options granted to key management personnel.

During the nine month period ended September 30, 2016, the Company:

Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.

As at September 30, 2016 and December 31, 2015, the following amounts are due to related parties:

		September 30, 2016		December 31, 2015
Clarence Smith (CEO)	Accounts payable and accrued liabilities	$	1,359	$	327

Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

XML 27 R17.htm IDEA: XBRL DOCUMENT

11. Commitments and Contingency

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingency

As at September 30, 2016, the Company has the following commitments:

Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year for providing research and development services.

XML 28 R18.htm IDEA: XBRL DOCUMENT

12. Subsequent Events

9 Months Ended

Sep. 30, 2016

Subsequent Events [Abstract]

Subsequent Events

Subsequent to the nine month period ended September 30, 2016, the Company:

Issued 1,250,000 shares of common stock to the President and CEO of the Company at $0.04 per share for gross proceeds of $50,000.00.

XML 29 R19.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America ("US GAAP") applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2015, included in the Company's Annual Report on Form 10-K, filed March 30, 2016, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Use of Estimates	Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.
Cash	Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments	Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 "Fair Value Measurements and Disclosures" which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At September 30, 2016 there were no other assets or liabilities subject to additional disclosure.
Income Taxes	The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 "Income Taxes." Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
Intangible assets - patent and patent application costs	The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at September 30, 2016, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company's patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2016.
Research and Development Costs	Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 28,600,000 stock options (September 30, 2015 – 14,600,000) and 6,500,000 warrants (September 30, 2015 – 12,262,500) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.
Share-Based Compensation	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 "Compensation – Stock Compensation", which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company's stock price on the date of issuance. The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 "Stock-Based Transactions with Nonemployees", which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common stock	Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty's performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions	A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements	In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements. Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company is reviewing this update to determine the impact it will have on its financial statements. Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements. Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements. Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy is effective December 16, 2016. The Company is evaluating this guidance and believes it will have little impact on the presentation of its financial statements. Accounting Standards Update 2015-02 - Consolidation (Topic 810) - Amendments to the Consolidation Analysis. This update provides guidance with respect to the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard which has little impact on the presentation of its financial statements. Accounting Standards Update 2015-01 - Income Statement—Extraordinary and Unusual Items (Subtopic 225-20). This Update is part of an initiative to reduce complexity in accounting standards (the Simplification Initiative). This Update eliminates from GAAP the concept of extraordinary items. The amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The Company has adopted this standard.

XML 30 R20.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Incentive Plan, Issuances

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

2015	Number of Shares		Value per Share		Total

February 2015		1,000,000	$	0.04	$	40,000
June 2015		100,000	$	0.07	$	7,000
		1,100,000			$	47,000

XML 31 R21.htm IDEA: XBRL DOCUMENT

7. Stock Options (Tables)

9 Months Ended

Sep. 30, 2016

Stock Options

Schedule of Share-based Compensation, Stock Options, Activity

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2015		14,600,000			0.05		0.03
Options granted		15,000,000			0.08		0.05
Options expired		(1,000,000	)		0.10		0.03
Outstanding, September 30, 2016		28,600,000			0.06		0.04	2.92

Schedule of valuation assumptions for options

	September 30, 2015			September 30, 2016
Risk-free interest rate		0.81	%		0.56	%
Dividend yield		0.00	%		0.00	%
Expected stock price volatility		125.00	%		125.00	%
Expected forfeiture rate		0.00	%		0.00	%
Expected life	4.81 years			3.94 years

Schedule of options by exercise price

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
	$
February 25, 2017		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2017		0.10		1,000,000		1,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		11,250,000
				28,600,000		22,850,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

8. Warrants (Tables)

9 Months Ended

Sep. 30, 2016

Warrants

Schedule of Warrant Activity

	Number of Warrants			Weighted Average Exercise Price
Balance, December 31, 2015		8,700,000		$	0.11
Expired		(2,200,000	)		0.10
Balance, September 30, 2016		6,500,000		$	0.11

Schedule of Stockholders' Equity Note, Warrants or Rights

Number of Warrants	Exercise Price ($)	Expiry Date
500,000	0.25	November 8, 2018
6,000,000	0.10	April 22, 2020
6,500,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Tables)

9 Months Ended

Sep. 30, 2016

Schedule of related party transactions

			September 30, 2016				December 31, 2015
Clarence Smith (CEO)	Accounts payable and accrued liabilities		$	1,359			$	327

XML 34 R24.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share	28,600,000	14,600,000
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share	6,500,000	12,262,500

XML 35 R25.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
4. Intangible Assets (Details Narrative) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 750	$ 0	$ 2,250	$ 0

XML 36 R26.htm IDEA: XBRL DOCUMENT

5. Convertible Note Payable and Credit Facility (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Accrued interest include accounts payable and accrued liabilities		$ 84,000
Issuance of common stock to settle		3,840,000
Fair value of the shares		$ 192,000
Fair value of the shares per share		$ 0.05
Gain on settlement on loan		$ 192,000
Stipulated the payment	$ 161,750
Common stock conversion shares	1,250,000
Common stock conversion price per share	$ 0.08
Short-term loans outstanding		90,000
Advances		$ 23,500

XML 37 R27.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Number of Shares		1,100,000
Value per Share	$ 0.07
Total	$ 7,000	$ 47,000
March 2016
Number of Shares	100,000
Value per Share	$ .07
Total	$ 7,000
February 2015
Number of Shares		1,000,000
Value per Share		$ .04
Total		$ 40,000
June 2015
Number of Shares		100,000
Value per Share		$ .07
Total		$ 7,000

XML 38 R28.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details) - $ / shares	9 Months Ended
7. Stock Options (Details) - $ / shares	Sep. 30, 2016	Sep. 30, 2015
Outstanding, ending	28,600,000
Weighted Average Fair Value, granted	$ .05	$ .03
Stock options
Outstanding, beginning	14,600,000
Options granted	15,000,000
Options expired	(1,000,000)
Outstanding, ending	28,600,000
Weighted Average Exercise Price beginning	$ .05
Weighted Average Exercise Price, granted	.08
Weighted Average Exercise Price, expired	.10
Weighted Average Exercise Price ending	.06
Weighted Average Fair Value, beginning	.03
Weighted Average Fair Value, granted	.05
Weighted Average Fair Value, expired	.03
Weighted Average Fair Value, ending	$ .04
Weighted Average Remaining Life (Years)	2 years 11 months 1 day

XML 39 R29.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details 1) - Stock options	9 Months Ended
7. Stock Options (Details 1) - Stock options	Sep. 30, 2016	Sep. 30, 2015
Risk-free interest rate	0.81%	0.56%
Dividend yield	0.00%	0.00%
Expected stock price volatility	125.00%	125.00%
Expected forfeiture rate	0.00%	0.00%
Expected life	4 years 9 months 22 days	3 years 11 months 8 days

XML 40 R30.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details 2)	Sep. 30, 2016 $ / shares shares
Number of Options Outstanding	28,600,000
Number of options exercisable	22,850,000
February 25, 2017
Weighed average exercise price ending \| $ / shares	$ 0.04
Number of Options Outstanding	2,000,000
Number of options exercisable	0
February 24, 2018
Weighed average exercise price ending \| $ / shares	$ 0.05
Number of Options Outstanding	1,000,000
Number of options exercisable	1,000,000
February 25, 2020
Weighed average exercise price ending \| $ / shares	$ 0.04
Number of Options Outstanding	4,000,000
Number of options exercisable	4,000,000
February 28, 2020
Weighed average exercise price ending \| $ / shares	$ 0.04
Number of Options Outstanding	5,000,000
Number of options exercisable	5,000,000
June 30, 2017
Weighed average exercise price ending \| $ / shares	$ 0.1
Number of Options Outstanding	1,000,000
Number of options exercisable	1,000,000
June 30, 2018
Weighed average exercise price ending \| $ / shares	$ 0.1
Number of Options Outstanding	600,000
Number of options exercisable	600,000
December 31, 2019
Weighed average exercise price ending \| $ / shares	$ 0.08
Number of Options Outstanding	15,000,000
Number of options exercisable	11,250,000

XML 41 R31.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details Narrative) - USD ($)	9 Months Ended
7. Stock Options (Details Narrative) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Aggregate intrinsic value	$ 398,000		$ 350,000
Weighted average fair value of stock options granted per share	$ .05	$ .03
Options
Common stock granted	16,600,000
Common Stock
Common stock granted	2,000,000

XML 42 R32.htm IDEA: XBRL DOCUMENT

8. Warrants (Details)	9 Months Ended
8. Warrants (Details)	Sep. 30, 2016 $ / shares shares
Outstanding, ending	28,600,000
Warrant
Outstanding, beginning	8,700,000
Warrants expired	(2,200,000)
Outstanding, ending	6,500,000
Weighted Average Exercise Price beginning \| $ / shares	$ .11
Weighted Average Exercise Price warrants expired \| $ / shares	.10
Weighted Average Exercise Price ending \| $ / shares	$ .11

XML 43 R33.htm IDEA: XBRL DOCUMENT

8. Warrants (Details 1)	9 Months Ended
8. Warrants (Details 1)	Sep. 30, 2016 $ / shares shares
Number of Warrants	6,500,000
Warrant One
Number of Warrants	500,000
Warrant Exercise Price \| $ / shares	$ .25
Expiry Date	November 8, 2018
Warrant Two
Number of Warrants	6,000,000
Warrant Exercise Price \| $ / shares	$ .10
Expiry Date	April 22, 2020

XML 44 R34.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (Details Narrative) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Dividends declared	$ 0	$ 0

XML 45 R35.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Accounts payable and accrued liabilities	$ 40,386	$ 45,388
Clarence Smith (CEO)
Accounts payable and accrued liabilities	$ 1,359	$ 327

XML 46 R36.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Professional fees	$ 39,664	$ 49,325	$ 147,977	$ 219,848
Payment to CFO			$ 54,000	36,000
Director
Professional fees				$ 8,780

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 48 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 49 138 1 false 22 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://protokinetix.com/taxonomy/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (Unaudited) Sheet http://protokinetix.com/role/BalanceSheets BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://protokinetix.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited) Sheet http://protokinetix.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://protokinetix.com/role/StatementOfStockholdersEquity STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://protokinetix.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - 1. Basis of Presentation - Going Concern Uncertainties Sheet http://protokinetix.com/role/BasisOfPresentation-GoingConcernUncertainties 1. Basis of Presentation - Going Concern Uncertainties Notes 7 false false R8.htm 00000008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - 3. Accounts Receivable Sheet http://protokinetix.com/role/AccountsReceivable 3. Accounts Receivable Notes 9 false false R10.htm 00000010 - Disclosure - 4. Intangible Assets Sheet http://protokinetix.com/role/IntangibleAssets 4. Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - 5. Convertible Note Payable and Credit Facility Sheet http://protokinetix.com/role/ConvertibleNotePayableAndCreditFacility 5. Convertible Note Payable and Credit Facility Notes 11 false false R12.htm 00000012 - Disclosure - 6. Common Shares Issued for Services Sheet http://protokinetix.com/role/CommonSharesIssuedForServices 6. Common Shares Issued for Services Notes 12 false false R13.htm 00000013 - Disclosure - 7. Stock Options Sheet http://protokinetix.com/role/StockOptions 7. Stock Options Notes 13 false false R14.htm 00000014 - Disclosure - 8. Warrants Sheet http://protokinetix.com/role/Warrants 8. Warrants Notes 14 false false R15.htm 00000015 - Disclosure - 9. Stockholders' Equity Sheet http://protokinetix.com/role/StockholdersEquity 9. Stockholders' Equity Notes 15 false false R16.htm 00000016 - Disclosure - 10. Related Party Transactions and Balances Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 10. Related Party Transactions and Balances Notes 16 false false R17.htm 00000017 - Disclosure - 11. Commitments and Contingency Sheet http://protokinetix.com/role/CommitmentsAndContingency 11. Commitments and Contingency Notes 17 false false R18.htm 00000018 - Disclosure - 12. Subsequent Events Sheet http://protokinetix.com/role/SubsequentEvents 12. Subsequent Events Notes 18 false false R19.htm 00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - 6. Common Shares Issued for Services (Tables) Sheet http://protokinetix.com/role/CommonSharesIssuedForServicesTables 6. Common Shares Issued for Services (Tables) Tables http://protokinetix.com/role/CommonSharesIssuedForServices 20 false false R21.htm 00000021 - Disclosure - 7. Stock Options (Tables) Sheet http://protokinetix.com/role/StockOptionsTables 7. Stock Options (Tables) Tables http://protokinetix.com/role/StockOptions 21 false false R22.htm 00000022 - Disclosure - 8. Warrants (Tables) Sheet http://protokinetix.com/role/WarrantsTables 8. Warrants (Tables) Tables http://protokinetix.com/role/Warrants 22 false false R23.htm 00000023 - Disclosure - 10. Related Party Transactions and Balances (Tables) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 10. Related Party Transactions and Balances (Tables) Tables http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 23 false false R24.htm 00000024 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) Details http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 24 false false R25.htm 00000025 - Disclosure - 4. Intangible Assets (Details Narrative) Sheet http://protokinetix.com/role/IntangibleAssetsDetailsNarrative 4. Intangible Assets (Details Narrative) Details http://protokinetix.com/role/IntangibleAssets 25 false false R26.htm 00000026 - Disclosure - 5. Convertible Note Payable and Credit Facility (Details Narrative) Sheet http://protokinetix.com/role/ConvertibleNotePayableAndCreditFacilityDetailsNarrative 5. Convertible Note Payable and Credit Facility (Details Narrative) Details http://protokinetix.com/role/ConvertibleNotePayableAndCreditFacility 26 false false R27.htm 00000027 - Disclosure - 6. Common Shares Issued for Services (Details) Sheet http://protokinetix.com/role/CommonSharesIssuedForServicesDetails 6. Common Shares Issued for Services (Details) Details http://protokinetix.com/role/CommonSharesIssuedForServicesTables 27 false false R28.htm 00000028 - Disclosure - 7. Stock Options (Details) Sheet http://protokinetix.com/role/StockOptionsDetails 7. Stock Options (Details) Details http://protokinetix.com/role/StockOptionsTables 28 false false R29.htm 00000029 - Disclosure - 7. Stock Options (Details 1) Sheet http://protokinetix.com/role/StockOptionsDetails1 7. Stock Options (Details 1) Details http://protokinetix.com/role/StockOptionsTables 29 false false R30.htm 00000030 - Disclosure - 7. Stock Options (Details 2) Sheet http://protokinetix.com/role/StockOptionsDetails2 7. Stock Options (Details 2) Details http://protokinetix.com/role/StockOptionsTables 30 false false R31.htm 00000031 - Disclosure - 7. Stock Options (Details Narrative) Sheet http://protokinetix.com/role/StockOptionsDetailsNarrative 7. Stock Options (Details Narrative) Details http://protokinetix.com/role/StockOptionsTables 31 false false R32.htm 00000032 - Disclosure - 8. Warrants (Details) Sheet http://protokinetix.com/role/WarrantsDetails 8. Warrants (Details) Details http://protokinetix.com/role/WarrantsTables 32 false false R33.htm 00000033 - Disclosure - 8. Warrants (Details 1) Sheet http://protokinetix.com/role/WarrantsDetails1 8. Warrants (Details 1) Details http://protokinetix.com/role/WarrantsTables 33 false false R34.htm 00000034 - Disclosure - 9. Stockholders' Equity (Details Narrative) Sheet http://protokinetix.com/role/StockholdersEquityDetailsNarrative 9. Stockholders' Equity (Details Narrative) Details http://protokinetix.com/role/StockholdersEquity 34 false false R35.htm 00000035 - Disclosure - 10. Related Party Transactions and Balances (Details) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetails 10. Related Party Transactions and Balances (Details) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 35 false false R36.htm 00000036 - Disclosure - 10. Related Party Transactions and Balances (Details Narrative) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative 10. Related Party Transactions and Balances (Details Narrative) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 36 false false All Reports Book All Reports pktx-20160930.xml pktx-20160930.xsd pktx-20160930_cal.xml pktx-20160930_def.xml pktx-20160930_lab.xml pktx-20160930_pre.xml true true ZIP 53 0001079973-16-001279-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-16-001279-xbrl.zip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�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end